Latest Microbiome Diagnostics News

Page 1 of 1
Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.
Ada Torres
Ada Torres
28 Oct 2025
Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.
Ada Torres
Ada Torres
28 Oct 2025
Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.
Ada Torres
Ada Torres
26 Aug 2025
Microba Life Sciences reports strong Q4 FY25 growth driven by record microbiome test sales and clinician adoption in Australia and the UK, while advancing its therapeutics pipeline and targeting regional break-even in FY26.
Ada Torres
Ada Torres
22 July 2025
Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.
Ada Torres
Ada Torres
22 July 2025
Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.
Ada Torres
Ada Torres
27 June 2025
Microba Life Sciences announces a $12.5 million equity raise, including a strategic $8.3 million investment from Sonic Healthcare, aiming to fuel growth in the UK and achieve regional break-even by FY26.
Ada Torres
Ada Torres
23 June 2025
Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.
Ada Torres
Ada Torres
23 June 2025
Microba Life Sciences reveals breakthrough data showing its MetaPanel™ test detects elusive gastrointestinal pathogens in 20% of chronic cases, enabling targeted treatment and complete symptom resolution.
Ada Torres
Ada Torres
21 May 2025
Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.
Ada Torres
Ada Torres
30 Apr 2025
Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.
Ada Torres
Ada Torres
30 Apr 2025
Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.
Ada Torres
Ada Torres
29 Jan 2025